AI assistant
Marksans Pharma Ltd. Earnings Release 2021
62142_rns_2020-11-06_ade0c8ec-42ca-4f75-ae13-fd53c0ff1941.pdf
Earnings Release
Open in viewerOpens in your device viewer
BSElimited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404
National Stock Exchange of India limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS
Enclosed herewith kindly find a News Release dated 6 th November, 2020 ofthe Company.
Yours faithfully, For1f~~r:-miled
Harshavardhan Panigrahi Company Secretary
Marksans Pharma Ltd.;
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road Oshiwara Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • E-mail: [email protected] . www.marksanspharma.com
Q2FY21Revenue at Rs.360.1 Cr.; growth of 36.3%
EBITDA atRs.86.8Cr., growth of 109.5%
Mumbai, November 6, 2020 - Marksans Pharma Ltd (NSE:MARKSANS;BSE Code:524404), one of the fastest growing pharmaceutical companies in Indiatoday announced financial results for the second quarter and half yearended September 30th, 2020.
Financial Highlights - Consolidated Financial Overview:
in Rs. Cr.
| Q2FY21 | Q2FY20 | YoY Growth(%) | 1HFY21 | 1HFY20 | YoY Growth(%) | |
|---|---|---|---|---|---|---|
| Total Revenue | 360.1 | 264.3 | 36.3% | 691.5 | 511.5 | 35.2% |
| EBITDA | 86.8 | 41.4 | 109.5% | 157.0 | 76.0 | 106.5% |
| EBITDA Margin% | 24.1% | 15.7% | 843 bps | 22.7% | 14.9% | 784 bps |
| PAT | 50.7 | 26.0 | 95.4% | 100.1 | 48.5 | 106.6% |
| PAT Margin% | 14.1% | 9.8% | 426 bps | 14.5% | 9.5% | 500 bps |
Consolidated Q2 FY21 (Y-o-Y)
- Total Revenuewas Rs.360.1 Cr. as compared to Rs. 264.3Cr. in Q2 FY20, an increase of 36.3%
- $\blacksquare$ EBITDA was Rs. 86.8 Cr. as compared to Rs. 41.4 Cr. in Q2 FY20, an increase of 109.5%
- EBITDA Margin stood at 24.1% as against 15.7% in Q2 FY20
- $\bar{a}$ PAT stood at Rs.50.7Cr. as compared to Rs. 26.0Cr. in Q2 FY20, a growth of 95.4%
Consolidated H1 FY21 (Y-o-Y)
- Total Revenue was Rs.691.5 Cr. as compared to Rs. 511.5Cr. in H1 FY20, an increase of 35.2%
- EBITDA was Rs.157.0 Cr. as compared to Rs. 76.0Cr. in H1 FY20, a growth of 106.5%
- EBITDA Margin stood at 22.7% as against 14.9% in H1 FY20
- PAT stood at Rs.100.1 Cr. as compared to Rs. 48.5 Cr. in H1 FY20, an increase of 106.6%
Commenting on the performance Mark Saldanha, Managing Director of the Company said "The Company turned in another quarter of exemplary performance and this was evidenced by a 36% revenue growth and a record EBITDA of Rs. 86.8 crore. I feel all the more delighted as it came in the background of the pandemic and was only achieved through the unflinching efforts of our employees along with support from all out stakeholders. We continue to remain cautiously optimistic of continuing the momentum in the future."
Business Performance
Revenue by Market:
in Rs. Cr.
| <br>"'<'<',~ | HiFY2i | HiFY20 | YoY Growth(%) | Mix(HiFY2i) % |
|---|---|---|---|---|
| Europe, UK- Formulation | 286.0 | 225.2 | 27.0% | 41.4% |
| US & North America-Formulation | 302.5 | 203.4 | 48.7% | 43.7% |
| Australia& NZ- Formulation | 69.4 | 61.9 | 12.1% | 10:0% |
| Rest of World(ROW) | 33.6 | 21.0 | 60.4% | 4.9% |
| ConsolidatedRevenue fromoperations | 691.5 | 511.5 | 35.2% | 100.0% |
Business Highlights
- Company achieved reven~e of Rs.286.0 Cr. from Europe, UK: Formulation business in H1FY21 as compared to Rs.225.2Cr. achieved during last year same period registering growth of 27.0%.
- US & North America Formulation business reported growth of 48.7% to Rs.302.5 Cr.in H1FY21
- Australia & NZ Formulation business revenue was at Rs.69.4Cr.in HHY21, registering growth of 12.1% YoY
- Rest of World Formulation business was Rs.33.6 crores in H1FY21
About Marksans Pharma Ltd
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India isengaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation inthe global markets. The company's manufacturing facilities are approved by several leadingregulatory agencies including USFDA, UKMHRA and Australian TGA. The company'srobust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic,Pain Management, Gastroenterological and Anti-allergies. The company ismarketing these products globally.
Jitendra Sharma, CFO Marksans Pharma Ltd Tel: +91 022 40012000 jite nd[email protected]
Dikshita Jain Christensen Investor Relations Tel: +912242150210 dj ai[email protected]
Registered Office
11th Floor, "GRANDEUR" Off Veera Desai Extension Road Oshiwara, Andheri West Mumbai, Maharashtra, 400053 Telephone: +91 2240012000 Fax: +91 224001 2011 CIN: L24110MH1992PLC066364 ISIN: INE750C01026 NSECode: MARKSANS SSECODE:524404 Website: http://www.marksanspharma.com